Cargando…
Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer
BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standa...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Berlin Heidelberg
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212905/ https://www.ncbi.nlm.nih.gov/pubmed/37231229 http://dx.doi.org/10.1186/s13550-023-00999-y |
_version_ | 1785047514787872768 |
---|---|
author | Margail, Charles Merlin, Charles Billoux, Tommy Wallaert, Maxence Otman, Hosameldin Sas, Nicolas Molnar, Ioana Guillemin, Florent Boyer, Louis Guy, Laurent Tempier, Marion Levesque, Sophie Revy, Alban Cachin, Florent Chanchou, Marion |
author_facet | Margail, Charles Merlin, Charles Billoux, Tommy Wallaert, Maxence Otman, Hosameldin Sas, Nicolas Molnar, Ioana Guillemin, Florent Boyer, Louis Guy, Laurent Tempier, Marion Levesque, Sophie Revy, Alban Cachin, Florent Chanchou, Marion |
author_sort | Margail, Charles |
collection | PubMed |
description | BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standard reconstructions. We also analyzed the diagnostic performances of the different sequences and the impact of the algorithm on lesion intensity and background measures. METHODS: We retrospectively included 30 patients with biochemical recurrence of prostate cancer who had undergone (68) Ga-PSMA-11 PET-CT. We simulated images produced using only a quarter, half, three-quarters, or all of the acquired data material reprocessed using the SubtlePET® denoising algorithm. Three physicians with different levels of experience blindly analyzed every sequence and then used a 5-level Likert scale to assess the series. The binary criterion of lesion detectability was compared between series. We also compared lesion SUV, background uptake, and diagnostic performances of the series (sensitivity, specificity, accuracy). RESULTS: VPFX-derived series were classified differently but better than standard reconstructions (p < 0.001) using half the data. Q.Clear series were not classified differently using half the signal. Some series were noisy but had no significant effect on lesion detectability (p > 0.05). The SubtlePET® algorithm significantly decreased lesion SUV (p < 0.005) and increased liver background (p < 0.005) and had no substantial effect on the diagnostic performance of each reader. CONCLUSION: We show that the SubtlePET® can be used for (68) Ga-PSMA scans using half the signal with similar image quality to Q.Clear series and superior quality to VPFX series. However, it significantly modifies quantitative measurements and should not be used for comparative examinations if standard algorithm is applied during follow-up. |
format | Online Article Text |
id | pubmed-10212905 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Springer Berlin Heidelberg |
record_format | MEDLINE/PubMed |
spelling | pubmed-102129052023-05-27 Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer Margail, Charles Merlin, Charles Billoux, Tommy Wallaert, Maxence Otman, Hosameldin Sas, Nicolas Molnar, Ioana Guillemin, Florent Boyer, Louis Guy, Laurent Tempier, Marion Levesque, Sophie Revy, Alban Cachin, Florent Chanchou, Marion EJNMMI Res Original Research BACKGROUND: (68) Ga-PSMA PET is the leading prostate cancer imaging technique, but the image quality remains noisy and could be further improved using an artificial intelligence-based denoising algorithm. To address this issue, we analyzed the overall quality of reprocessed images compared to standard reconstructions. We also analyzed the diagnostic performances of the different sequences and the impact of the algorithm on lesion intensity and background measures. METHODS: We retrospectively included 30 patients with biochemical recurrence of prostate cancer who had undergone (68) Ga-PSMA-11 PET-CT. We simulated images produced using only a quarter, half, three-quarters, or all of the acquired data material reprocessed using the SubtlePET® denoising algorithm. Three physicians with different levels of experience blindly analyzed every sequence and then used a 5-level Likert scale to assess the series. The binary criterion of lesion detectability was compared between series. We also compared lesion SUV, background uptake, and diagnostic performances of the series (sensitivity, specificity, accuracy). RESULTS: VPFX-derived series were classified differently but better than standard reconstructions (p < 0.001) using half the data. Q.Clear series were not classified differently using half the signal. Some series were noisy but had no significant effect on lesion detectability (p > 0.05). The SubtlePET® algorithm significantly decreased lesion SUV (p < 0.005) and increased liver background (p < 0.005) and had no substantial effect on the diagnostic performance of each reader. CONCLUSION: We show that the SubtlePET® can be used for (68) Ga-PSMA scans using half the signal with similar image quality to Q.Clear series and superior quality to VPFX series. However, it significantly modifies quantitative measurements and should not be used for comparative examinations if standard algorithm is applied during follow-up. Springer Berlin Heidelberg 2023-05-25 /pmc/articles/PMC10212905/ /pubmed/37231229 http://dx.doi.org/10.1186/s13550-023-00999-y Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . |
spellingShingle | Original Research Margail, Charles Merlin, Charles Billoux, Tommy Wallaert, Maxence Otman, Hosameldin Sas, Nicolas Molnar, Ioana Guillemin, Florent Boyer, Louis Guy, Laurent Tempier, Marion Levesque, Sophie Revy, Alban Cachin, Florent Chanchou, Marion Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title | Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title_full | Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title_fullStr | Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title_full_unstemmed | Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title_short | Imaging quality of an artificial intelligence denoising algorithm: validation in (68)Ga PSMA-11 PET for patients with biochemical recurrence of prostate cancer |
title_sort | imaging quality of an artificial intelligence denoising algorithm: validation in (68)ga psma-11 pet for patients with biochemical recurrence of prostate cancer |
topic | Original Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10212905/ https://www.ncbi.nlm.nih.gov/pubmed/37231229 http://dx.doi.org/10.1186/s13550-023-00999-y |
work_keys_str_mv | AT margailcharles imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT merlincharles imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT billouxtommy imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT wallaertmaxence imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT otmanhosameldin imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT sasnicolas imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT molnarioana imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT guilleminflorent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT boyerlouis imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT guylaurent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT tempiermarion imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT levesquesophie imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT revyalban imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT cachinflorent imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer AT chanchoumarion imagingqualityofanartificialintelligencedenoisingalgorithmvalidationin68gapsma11petforpatientswithbiochemicalrecurrenceofprostatecancer |